INJE UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION;인제대학교 산학협력단;GENEUIN-TECH CO., LTD.;(주)지뉴인텍
发明人:
YOUN, Hyun Joo,윤현주,HAN, Eun Yeong,한은영
申请号：
KRKR2019/000651
公开号：
WO2019/177256A1
申请日:
2019.01.16
申请国别(地区):
KR
年份:
2019
代理人:
摘要：
The present invention relates to a multivalent live influenza vaccine platform using recombinant adenoviruses. The present invention is a live attenuated vaccine platform using recombinant viruses, which is easy to inoculate since the vaccine exhibits a vaccine action by infecting the respiratory system like an influenza virus and is a novel vaccine that does not require the mixing of viruses as compared to vaccines using a mixture of a plurality of single vaccines since the novel vaccine is a multivalent vaccine in which two types are fused together. The vaccine, which contains two influenza antigens fused into a single gene inserted into a recombinant virus, is the first to use a structurally independent HA1 gene, which uses about half, not the entirety, of the HA gene of influenza, to fuse several types of HA genes together. When mice were inoculated with the recombinant virus by a nasal aspiration method, it was confirmed that the vaccine was an effective vaccine for inducing a vaccine effect by two inoculations, and the vaccine platform of the present invention is expected to be useful in the development of a human influenza infection vaccine.La présente invention porte sur une plateforme de vaccin antigrippal vivant multivalent utilisant des adénovirus recombinants. L'invention concerne une plateforme de vaccin vivant atténué utilisant des virus recombinants, qui est facile à inoculer puisque le vaccin agit en infectant le système respiratoire comme un virus de la grippe et est un nouveau vaccin qui ne nécessite pas le mélange de virus par rapport à des vaccins utilisant un mélange d'une pluralité de vaccins uniques étant donné que le nouveau vaccin est un vaccin multivalent dans lequel deux types sont fusionnés ensemble. Le vaccin, qui contient deux antigènes de la grippe fusionnés en un seul gène inséré dans un virus recombinant, est le premier à utiliser un gène HA1 structurellement Indépendant, qui utilise environ la moitié, et non la totalité, du gène HA
